# A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB

> **NCT06122454** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xi'an Xintong Pharmaceutical Research Co.,Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Efficacy
- Safety
- Pharmacokinetics

## Interventions

- **DRUG:** Hepenofovir Fumarate Tablets

## Key facts

- **NCT ID:** NCT06122454
- **Lead sponsor:** Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-10
- **Primary completion:** 2024-06-06
- **Final completion:** 2024-12-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06122454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06122454, "A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06122454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*